Premium
A pH‐Sensitive Zwitterionic Iron Complex Probe with High Biocompatibility for Tumor‐Specific Magnetic Resonance Imaging
Author(s) -
Han Jiamei,
Liang Guohai,
Xing Da
Publication year - 2019
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201901117
Subject(s) - magnetic resonance imaging , in vivo , biocompatibility , mri contrast agent , chemistry , nuclear magnetic resonance , biophysics , contrast (vision) , biology , optics , medicine , physics , microbiology and biotechnology , organic chemistry , radiology
Abstract Accurate diagnosis of tumor characteristics, including its location and boundary, is of immense value to subsequent therapy. Activatable magnetic resonance imaging (MRI) contrast agents that respond to tumor‐specific microenvironments, such as the redox state, pH, and enzyme activity, enable better mapping of tumor tissue. However, the practical application of most reported activatable agents is hampered by problems including potential toxicity, inefficient elimination, and slow activation. In this study, we developed a zwitterionic iron complex (Fe‐ZDS) as a positive MRI contrast agent for tumor‐specific imaging. Fe‐ZDS could dissociate in weakly acidic solution rapidly, accompanied by clear longitudinal relaxivity ( r 1 ) enhancement, which enabled the complex to act as a pH‐sensitive contrast agent for tumor‐specific MR imaging. In vivo experiments showed that Fe‐ZDS rapidly enhanced the tumor‐to‐normal contrast ratio by >40 %, which assisted in distinguishing the tumor boundary. Furthermore, Fe‐ZDS circulated freely in the bloodstream and was excreted relatively safely via kidneys owing to its zwitterionic nature. Therefore, Fe‐ZDS is an ideal candidate for a tumor‐specific MRI contrast agent and holds considerable potential for clinical translation.